Mackenzie Financial Corp Sells 141,733 Shares of Hologic, Inc. $HOLX

Mackenzie Financial Corp decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 12.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,025,401 shares of the medical equipment provider’s stock after selling 141,733 shares during the period. Mackenzie Financial Corp owned 0.46% of Hologic worth $69,204,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of HOLX. The Manufacturers Life Insurance Company grew its holdings in shares of Hologic by 294.3% in the second quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock valued at $718,223,000 after acquiring an additional 8,227,318 shares in the last quarter. Invesco Ltd. lifted its holdings in Hologic by 72.5% during the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after acquiring an additional 3,505,828 shares during the period. Norges Bank bought a new stake in Hologic during the second quarter worth $180,055,000. Black Creek Investment Management Inc. boosted its position in Hologic by 26.1% in the second quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider’s stock worth $262,453,000 after purchasing an additional 832,444 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. purchased a new position in Hologic in the second quarter worth $48,283,000. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

NASDAQ:HOLX opened at $75.41 on Thursday. The company has a market capitalization of $16.83 billion, a P/E ratio of 31.42, a P/E/G ratio of 2.25 and a beta of 0.73. The business has a fifty day simple moving average of $75.10 and a two-hundred day simple moving average of $72.57. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $75.75.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The firm had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. The firm’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.87 EPS. On average, analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

HOLX has been the subject of several research analyst reports. Argus lowered Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. BNP Paribas Exane downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price objective for the company. in a report on Friday, November 21st. Finally, Evercore lowered shares of Hologic from an “outperform” rating to an “in-line” rating and lowered their price objective for the stock from $79.00 to $78.00 in a research report on Monday, January 5th. Two investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $78.42.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.